Skip to content

Net Income at other companies

Insulet logo
InsuletPODD
$91.1M+157%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$20.39M+84.4%
Medtronic logo
MedtronicMDT
$1.24B+17.8%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$14.98M-1,206%
Mannkind logo
MannkindMNKD
-$16.62M-226%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
-$21.9M+23.6%

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s net income?
Embecta Corp. (EMBC) reported net income of -$4.1M in Q1 2026.
How has Embecta Corp.'s net income changed year-over-year?
Embecta Corp.'s net income decreased by 117.4% year-over-year, from $23.5M to -$4.1M.
What is the long-term trend for Embecta Corp.'s net income?
Over 4 years (2021 to 2025), Embecta Corp.'s net income has grown at a -30.7% compound annual growth rate (CAGR), from $414.8M to $95.4M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.